Evaluation of Staphylococcus aureus Infections in Children

Abstract

Aim: Staphylococcus aureus is the most common infectious agent worldwide which leads to morbidity and mortality. Community and hospital acquired infections can range to skin infections to life-threatening infections. In our study, we attempted to evaluate demographic, clinical, and laboratory parameters and the prognosis of children with S. aureus infection. Methods: Children infected with S. aureus at the Department of Paediatric Infectious Disease, Selcuk University Faculty of Medicine, from 2014 to 2022 were analysed retrospectively. Patients were evaluated for MRSA, MSSA, and community or hospital-acquired infections. Results: A total of 116 children's detected specimens were collected; 31.9% contained MRSA and 68.1% contained MSSA. The proportion of community-acquired (CA) infections was 88.8%, while hospital-acquired (HA) infections were 11.2%. MSSA was more common in the CA-S. aureus group, while MRSA was more common in the HA-S. aureus group (p=.025). The most common clinical manifestations included soft tissue infection, lymphadenitis, cutaneous infection, osteomyelitis, and septic arthritis. Each patient was treated with antibiotics, 77.59% of patients was required hospitalization. In 62.9% of the patients, surgical intervention (drainage or debridement) was performed. Despite 86.2% of the patients were cured, infection persisted in nine patients with epidermolysis bullosa, CIPA syndrome, and bone implants. One patient with shunt meningitis died. Conclusions: S. aureus cause both CA and HA superficial or invasive infections, in children. Especially in life-threatening infections, appropriate antibiotic therapy is critical for preventing mortality until an antibiogram culture result is obtained. The patient's clinical condition and regional antibiotic resistance should be considered when prescribing antibiotics empirically.

Keywords

• Child
• invasive infections
• Staphylococcus aureus
• skin and soft tissue infections

Çocuklarda Staphylococcus aureus Enfeksiyonlarının Değerlendirilmesi

Abstract

Amaç: Staphylococcus aureus, dünya çapında morbidite ve mortaliteye yol açan en yaygın enfeksiyöz ajanlardandır. Toplumdan ve hastaneden edinilen enfeksiyonlar cilt enfeksiyonlarından hayatı tehdit eden enfeksiyonlara kadar değişebilmektedir. S. aureus enfeksiyonlarının tedavisi, antibiyotik direnci ve aşı eksikliği nedeniyle zordur. Çalışmamızda S. aureus enfeksiyonu olan çocukların demografik, klinik ve laboratuvar parametrelerini ve prognozunu değerlendirmeyi amaçladık. Yöntem: Selçuk Üniversitesi Tıp Fakültesi Çocuk Enfeksiyon Hastalıkları Bölümünde 2014-2022 yılları arasında, S.aureus ile enfekte çocuklar retrospektif olarak analiz edildi. Hastalar MRSA, MSSA ve toplumdan veya hastane kaynaklı enfeksiyonlar açısından değerlendirildi. Bulgular: Toplam 116 çocuk örneğinin %31,9'u MRSA ve %68,1'i MSSA idi. Toplum kökenli (TK) enfeksiyonlar %88,8 iken, hastane kaynaklı (HK) enfeksiyonların oranı %11,2 idi. MSSA, TK enfeksiyonda daha yaygınken, MRSA ise HK enfeksiyonda daha yaygındı (p=.025). En sık klinik belirtiler yumuşak doku enfeksiyonu, lenfadenit, cilt enfeksiyonu, osteomiyelit ve septik artritti. Her hastaya antibiyotik tedavisi uygulandı, hastaların %77.59'unun hastaneye yatırılması gerekti. Hastaların %62,9'una cerrahi girişim (drenaj ve debridman) uygulandı. Hastaların %86.2'sinin iyileşmesine rağmen, epidermolizis bülloza, CIPA sendromu veya kemik implantları olan dokuz hastada tekrarlayan enfeksiyonlar saptandı. Şant menenjiti olan bir hasta öldü. Sonuç: S. aureus, çocuklarda hem toplumdan hem de hastane kaynaklı yüzeysel veya invaziv enfeksiyonlara neden olmaktadır. Özellikle yaşamı tehdit eden enfeksiyonlarda, antibiyogram kültür sonucu çıkıncaya kadar uygun antibiyotik tedavisi mortalitenin önlenmesi açısından kritik öneme sahiptir. Ampirik antibiyotik başlanırken hastanın klinik durumu ve bölgesel antibiyotik direnci göz önünde bulundurulmalıdır.

Keywords

• Çocuk
• invaziv enfeksiyonlar
• Staphylococcus aureus
• deri ve yumuşak doku enfeksiyonları

References

1. 1.Centers for Disease Control and Prevention (CDC). Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infection-Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2003;52(5):88.
2. 2.Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46 Suppl 5: S344-9.
3. 3. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603-61.
4. 4. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am. 2009;23(1):17-34.
5. 5. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. 2005;3(12):948-58.
6. 6. Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2013;13(1):43-54.
7. 7. Rasigade JP, Vandenesch F. Staphylococcus aureus: a pathogen with still unresolved issues. Infect Genet Evol. 2014; 21:510-4.
8. 8.Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763.

9. 9. Charlebois, E.D., Perdreau-Remington, F., Kreiswirth, B., et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2004;39(1):47- 54.
10. 10. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clinical microbiology reviews. 2010;23(3):616-87.
11. 11. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated methicillin resistant Staphylococcus aureus. The Lancet. 2010;375(9725):1557-68.
12. 12. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical, and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis. 2007; 44:471.
13. 13.Gomes RT, Lyra TG, Alves NN, Caldas RM, Barberino MG, Nascimento-Carvalho CM. Methicillin-resistant and methicillin-susceptible community-acquired Staphylococcus aureus infection among children. Braz J Infect Dis. 2013;17(5):573-578.
14. 14.Al Kindi A, Alkahtani AM, Nalubega M, et al. Staphylococcus aureus Internalized by Skin Keratinocytes Evade Antibiotic Killing. Front Microbiol. 2019; 10:2242.
15. 15. Gottlieb M, DeMott JM, Hallock M, Peksa GD. Systemic Antibiotics for the Treatment of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-Analysis. Ann Emerg Med 2019; 73:8.
16. 16. Howard-Jones AR, Al Abdali K, Britton PN. Acute bacterial lymphadenitis in children: a retrospective, cross-sectional study. Eur J Pediatr. 2023;182(5):2325-33.
17. 17. Wen Y, Wang C, Jia H, Liu T, Yu J, Zhang M. Comparison of diagnosis and treatment of MSSA and MRSA osteomyelitis in children: a case-control study of 64 patients. J Orthop Surg Res. 2023;18(1):197.
18. 18. Messina AF, Namtu K, Guild M, Dumois JA, Berman DM. Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis. Pediatr Infect Dis J. 2011;30(12):1019-21.
19. 19. Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin resistant Staphylococcus aureus. J Pediatr Orthop 2006; 26:703.
20. 20. Cea-Pereiro JC, Garcia-Meijide J, Mera-Varela A, Gomez-Reino JJ. A comparison between septic bursitis caused by Staphylococcus aureus and those caused by other organisms. Clin Rheumatol. 2001;20(1):10-14.
21. 21. Aguilera-Alonso D, Kirchschläger Nieto S, Ara Montojo MF, et al. Staphylococcus aureus Community-acquired Pneumonia in Children After 13-Valent Pneumococcal Vaccination (2008-2018): Epidemiology, Clinical Characteristics and Outcomes. Pediatr Infect Dis J. 2022;41(5): e235-e242.
22. 22. American Academy of Pediatrics. Staphylococcus aureus. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.678.
23. 23. Suryati BA, Watson M. Staphylococcus aureus bacteraemia in children: a 5-year retrospective review. J Paediatr Child Health 2002; 38:290.
24. 24. McNeil JC, Ligon JA, Hulten KG, et al. Staphylococcus aureus Infections in Children With Congenital Heart Disease. J Pediatric Infect Dis Soc 2013; 2:337.
25. 25. Vallejo JG, Cain AN, Mason EO, Kaplan SL, Hultén KG. Staphylococcus aureus Central Nervous System Infections in Children. Pediatr Infect Dis J. 2017;36(10):947-951.
26. 26. Ligon J, Kaplan SL, Hulten KG, et al. Staphylococcus aureus bacteremia without a localizing source in pediatric patients. Pediatr Infect Dis J 2014; 33: e132. 14.
27. 27. Hamdy RF, Dona D, Jacobs MB, Gerber JS. Risk Factors for Complications in Children with Staphylococcus aureus Bacteremia. J Pediatr 2019; 208:214.
28. 28. Paintsil E. Pediatric community-acquired methicillin-resistant Staphylococcus aureus infection and colonization: trends and management. Curr Opin Pediatr 2007; 19:75.
29. 29. Şanlı K. Susceptibility Patterns of Community-acquired and Hospital-acquired Staphylococcus aureus Strains Against Various Antimicrobials. İKSSTD 2020;12(2):188-93